JP2011526608A - グリコサミノグリカンを含む医薬組成物及び慢性潰瘍の処理へのその使用 - Google Patents

グリコサミノグリカンを含む医薬組成物及び慢性潰瘍の処理へのその使用 Download PDF

Info

Publication number
JP2011526608A
JP2011526608A JP2011515493A JP2011515493A JP2011526608A JP 2011526608 A JP2011526608 A JP 2011526608A JP 2011515493 A JP2011515493 A JP 2011515493A JP 2011515493 A JP2011515493 A JP 2011515493A JP 2011526608 A JP2011526608 A JP 2011526608A
Authority
JP
Japan
Prior art keywords
composition
molecular weight
low molecular
sulfo
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011515493A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011526608A5 (enExample
Inventor
エンシナ，イバン ロペス−ベルモンテ
マヨルドモ，マリア デ ロス アンヘレス カナレス
ミランダ，エレナ セバデラ
Original Assignee
ラボラトリオス ファルマセウティコス ロビ，ソシエダッド アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラボラトリオス ファルマセウティコス ロビ，ソシエダッド アノニマ filed Critical ラボラトリオス ファルマセウティコス ロビ，ソシエダッド アノニマ
Publication of JP2011526608A publication Critical patent/JP2011526608A/ja
Publication of JP2011526608A5 publication Critical patent/JP2011526608A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2011515493A 2008-07-01 2009-06-30 グリコサミノグリカンを含む医薬組成物及び慢性潰瘍の処理へのその使用 Pending JP2011526608A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP200802002 2008-07-01
ES200802002A ES2340902B1 (es) 2008-07-01 2008-07-01 Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
PCT/ES2009/070264 WO2010000904A1 (es) 2008-07-01 2009-06-30 Composición farmacéutica con glicosaminoglicanos y su uso en tratamiento de úlceras crónicas

Publications (2)

Publication Number Publication Date
JP2011526608A true JP2011526608A (ja) 2011-10-13
JP2011526608A5 JP2011526608A5 (enExample) 2014-08-07

Family

ID=41319881

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011515493A Pending JP2011526608A (ja) 2008-07-01 2009-06-30 グリコサミノグリカンを含む医薬組成物及び慢性潰瘍の処理へのその使用

Country Status (15)

Country Link
US (2) US20110201572A1 (enExample)
EP (1) EP2308497B1 (enExample)
JP (1) JP2011526608A (enExample)
CN (1) CN102176915A (enExample)
AU (1) AU2009265623B2 (enExample)
BR (1) BRPI0913839A2 (enExample)
CA (1) CA2766483C (enExample)
CY (1) CY1115780T1 (enExample)
DK (1) DK2308497T3 (enExample)
ES (2) ES2340902B1 (enExample)
MX (1) MX2010014552A (enExample)
PL (1) PL2308497T3 (enExample)
PT (1) PT2308497E (enExample)
RU (1) RU2011103459A (enExample)
WO (3) WO2010000906A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021119148A (ja) * 2015-03-20 2021-08-12 オーフス ウニベルシテット リポタンパク質代謝障害の治療のためのｐｃｓｋ９阻害剤

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2357601B1 (es) * 2011-01-26 2012-03-21 Laboratorios Farmacéuticos Rovi, S.A. Procedimiento de preparación de derivados de glicosaminoglicanos donadores de óxido n�?trico y su uso en tratamiento de úlceras crónicas.
JP2012245943A (ja) * 2011-05-31 2012-12-13 Hitachi Automotive Systems Ltd 制御装置
JP5942133B2 (ja) * 2012-09-11 2016-06-29 学校法人関西文理総合学園 蛍光プローブ及びこれを用いた酵素活性検出方法
EP3273239A1 (en) 2016-07-19 2018-01-24 Laboratorios Farmacéuticos Rovi, S.A. Procedure of analysis of glycosaminoglycans, heparins and their derivatives by nuclear magnetic resonance
JP7333919B2 (ja) * 2017-09-05 2023-08-28 エクセル メッド、エルエルシー 虚血を治療するためのヘパリン組成物
ES2792298B2 (es) * 2020-04-27 2022-04-20 Farm Rovi Lab Sa Procedimiento para la obtencion de heparinas de bajo peso molecular y heparinas de bajo peso molecular obtenidas por el mismo

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004A (en) * 1849-01-09 chinnqck

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7808292A (nl) * 1977-08-08 1979-02-12 Choay Sa Heparine-preparaten vrij van minerale zouten, in het bijzonder oxalaten, en een werkwijze ter bereiding daarvan.
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
FR2482611B1 (fr) * 1980-05-14 1986-03-07 Pharmindustrie Nouveaux polysaccharides sulfates, procedes pour leur preparation et leur utilisation comme medicaments
IT1245907B (it) * 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.
CA2310422A1 (en) * 1997-11-20 1999-06-03 Ikuo Yamashina Low-molecular heparin modification and remedy for skin ulcer
ES2161615B1 (es) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
WO2002077155A2 (en) 2001-01-08 2002-10-03 Human Genome Sciences, Inc. Keratinocyte growth factor-2
CU23043A1 (es) 2001-12-20 2005-05-20 Ct Ingenieria Genetica Biotech Composicion farmaceutica que contiene factor de crecimiento epidrmico (egf) para la prevencion de la amputacion de pie diabetico.
AU2003219421A1 (en) 2002-05-02 2003-11-17 Pfizer Products Inc. Treatment of diabetes and diabetic complications with nhe-1 inhibitors
US20060040896A1 (en) * 2004-08-18 2006-02-23 Paringenix, Inc. Method and medicament for anticoagulation using a sulfated polysaccharide with enhanced anti-inflammatory activity
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004A (en) * 1849-01-09 chinnqck

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN5011009797; ＫＡＬＡＮＩ　Ｍ．: 'ＥＦＦＥＣＴ　ＯＦ　ＤＡＬＴＥＰＡＲＩＮ　ＯＮ　ＨＥＡＬＩＮＧ　ＯＦ　ＣＨＲＯＮＩＣ　ＦＯＯＴ　ＵＬＣＥＲＳ　ＩＮ　ＤＩＡＢＥＴＩＣ　ＰＡＴＩＥＮＴＳ　以下備考' ＤＩＡＢＥＴＥＳ　ＣＡＲＥ Ｖ２６　Ｎ９, 200309, Ｐ２５７５-２５８０ *
JPN5011009798; ＫＡＬＡＮＩ　Ｍ．: 'ＢＥＮＥＦＩＣＩＡＬ　ＥＦＦＥＣＴＳ　ＯＦ　ＤＡＬＴＥＰＡＲＩＮ　ＯＮ　ＨＡＥＭＯＳＴＡＴＩＣ　ＦＵＮＣＴＩＯＮ　ＡＮＤ　ＬＯＣＡＬ　ＴＩＳＳＵＥ　ＯＸＹＧＥＮＡＴＩＯＮ　以下備考' ＴＨＲＯＭＢＯＳＩＳ　ＲＥＳＥＡＲＣＨ Ｖ１２０, 2007, Ｐ６５３-６６１ *
JPN5011009799; ＪＩＶＥＧＡＲＤ　Ｌ: 'ＥＦＦＥＣＴＳ　ＯＦ　ＴＨＲＥＥ　ＭＯＮＴＨＳ　ＯＦ　ＬＯＷ　ＭＯＬＥＣＵＬＡＲ　ＷＥＩＧＨＴ　ＨＥＰＡＲＩＮ　（ＤＡＬＴＥＰＡＲＩＮ）　ＴＲＥＡＴＭＥＮＴ　以下備考' ＥＵＲＯＰＥＡＮ　ＪＯＵＲＮＡＬ　ＯＦ　ＶＡＳＣＵＬＡＲ　ＡＮＤ　ＥＮＤＯＶＡＳＣＵＬＡＲ　ＳＵＲＧＥＲＹ Ｖ２９　Ｎ２, 20050201, Ｐ１９０-１９８, ＳＡＵＮＤＥＲＳ *
JPN5011009800; ＲＯＺＩＮ　Ａ．　Ｐ．: 'ＲＥＣＡＬＣＩＴＲＡＮＴ　ＬＥＧ　ＵＬＣＥＲ　ＤＵＥ　ＴＯ　ＭＩＸＥＤ　ＣＯＮＮＥＣＴＩＶＥ　ＴＩＳＳＵＥ　ＤＩＳＥＡＳＥ' ＴＨＥ　ＮＥＴＨＥＲＬＡＮＤＳ　ＪＯＵＲＮＡＬ　ＯＦ　ＭＥＤＩＣＩＮＥ Ｖ６４　Ｎ３, 200603, Ｐ９１-９４ *
JPN5011009801; ＲＵＬＬＡＮ　Ｍ．: 'ＥＮＳＡＹＯ　ＣＬＩＮＩＣＯ，　ＣＯＮＴＲＯＬＡＤＯ　ＣＯＮ　ＰＬＡＣＥＢＯ，　ＴＲＩＰＬＥ　ＣＩＥＧＯ，　ＰＡＲＡ　ＥＶＡＬＵＡＲ　ＬＡ　ＥＦＩＣＡＣＩＡ　以下備考' ＡＴＥＮ　ＰＲＩＭＡＲＩＡ Ｖ３１　Ｎ８, 2003, Ｐ５３９-５４４ *
JPN6013061878; Ｌ．Ｔｏｒｋｖｉｓｔ　ｅｔ．ａｌ．: 'Ｌｏｗ　ｍｏｌｅｃｕｌａｒ　ｗｅｉｇｈｔ　ｈｅｐａｒｉｎ　ａｓ　ａｄｊｕｖａｎｔ　ｔｈｅｒａｐｙ　ｉｎ　ａｃｔｉｖｅ　ｕｌｃｅｒａｔｉｖｅ　ｃｏｌｉｔｉｓ' Ａｌｉｍｅｎｔ　Ｐｈａｒｍａｃｏｌ　Ｔｈｅｒ Ｖｏｌ．１３，Ｎｏ．１０, 1999, ｐ．１３２３-１３２８ *
JPN6013061879; 戸田憲一ら: '新しいヘパリン修飾体の皮膚創傷治癒促進効果' 薬理と臨床 第１０巻，第５号, 2000, ｐ．３９９-４０４ *
JPN6013061882; 原武ら: 'ｔｏｐｉｃａｌ　ｈａｅｍｏｔｈｅｒａｐｙが有効であった難治性糖尿病性足趾潰瘍' 皮膚病診療 Ｖｏｌ．３０，Ｎｏ．６, 2008, ｐ．６９５-６９８ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021119148A (ja) * 2015-03-20 2021-08-12 オーフス ウニベルシテット リポタンパク質代謝障害の治療のためのｐｃｓｋ９阻害剤

Also Published As

Publication number Publication date
EP2308497B1 (en) 2014-04-16
WO2010000905A1 (es) 2010-01-07
CN102176915A (zh) 2011-09-07
US20110201572A1 (en) 2011-08-18
MX2010014552A (es) 2011-04-26
EP2308497A1 (en) 2011-04-13
WO2010000906A1 (es) 2010-01-07
AU2009265623B2 (en) 2014-11-20
RU2011103459A (ru) 2012-08-10
US9211305B2 (en) 2015-12-15
PL2308497T3 (pl) 2014-10-31
ES2340902A1 (es) 2010-06-10
ES2476966T3 (es) 2014-07-15
PT2308497E (pt) 2014-07-24
BRPI0913839A2 (pt) 2015-10-20
WO2010000904A1 (es) 2010-01-07
CA2766483A1 (en) 2010-01-07
CY1115780T1 (el) 2017-01-25
DK2308497T3 (da) 2014-07-14
US20140066402A1 (en) 2014-03-06
AU2009265623A1 (en) 2010-01-07
CA2766483C (en) 2017-01-17
ES2340902B1 (es) 2011-05-03

Similar Documents

Publication Publication Date Title
US9211305B2 (en) Pharmaceutical compositions with glycosaminoglycans and use thereof in the treatment of chronic ulcers
US7902171B2 (en) Composition for treating inflammatory diseases
Zhang et al. The clinical use of Fondaparinux: A synthetic heparin pentasaccharide
EP2794666B1 (en) Use of chemically modified heparin derivates in sickle cell disease
EP0347588A1 (en) Heparin derivatives and process for their preparation
JP2003506310A (ja) ヘパリン及びアデノシドａ２アゴニストの組合せで、又はアデノシンでの閉塞性末梢血管疾患及び冠状動脈疾患の治療
EP2025687A1 (en) Process for the preparation of heparanase-inhibiting sulfated hyaluronates and products obtained thereby
WO2000006608A1 (en) Novel glycosaminoglycan and drug compositions containing the same
EP0466315A2 (en) Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
CN1161124C (zh) 具有抗凝集/抗血栓形成作用的硫酸化低聚糖类化合物
AU694177B2 (en) Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
JP4051099B2 (ja) 低分子化ヘパリン、その製造法及び医薬組成物
WO2011038047A1 (en) Methods of treatment with a low molecular weight heparin composition
EP1731131A1 (en) Hgf production accelerator containing heparin-like oligosaccharide
CN1612741A (zh) 硫酸化葡糖胺聚糖在建立妇女有效分娩中的用途
JP6980018B2 (ja) 内因系テンナーゼ複合体を阻害するオリゴ糖、その製造方法と用途
CN1543983A (zh) 用于创伤护理的药物组合
Szczubialka et al. Heparin-a key drug in the treatment of the circulatory degenerative diseases: controlling its action with polymers
JP2018524067A (ja) アンチトロンビン−ヘパリン組成物を利用する医療機器、システムおよび方法
CN113388044A (zh) 一种蜗牛糖胺聚糖化合物、其药学上可接受的盐、制备方法及应用
HK1209334A1 (en) Chondroitin complexes for transcutaneous absorption
CN118459619A (zh) 一种半乳糖基化糖胺聚糖及其组合物与其制备方法和应用
FR2637804A1 (fr) Compositions pharmaceutiques contenant un derive d'heparine partiellement n-desulfate a activite antithrombotique
WO2005079817A1 (en) Affinity purified heparin/heparan sulfate for controlling the biological activity of the fgf receptor
HK1199893B (en) Use of chemically modified heparin derivates in sickle cell disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140314

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140617

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140617

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141104